FRANKFURT, March 9 (Reuters) - Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...

One woman who took part in research and had breast cancer detected says she feels "incredibly lucky".

A new study finds AI can potentially detect artery calcification in routine mammograms, helping identify women at risk of ...

A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients has missed its primary endpoint, tarnishing the record of a drug that hit the mark in adjuvant and second-line settings.

Suspicious cells build up in mice that haven’t given birth, a new study finds. They could help explain a longstanding mystery ...

It may be best not to go off-script when it comes to breast cancer. Roughly 1 in 8 US women are expected to be diagnosed with invasive breast cancer at some point. It’s the most common cancer in women ...

A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...

Roche Holdings AG on Monday shared results from the phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients. Trial Misses Primary Goal The trial ...

persevERA is the first of two distinct Phase III studies in the first-line setting; the pionERA study of giredestrant in combination with physician’s choice of cyclin-dependent kinase (CDK)4/6 ...

Organizers say hundreds of businesses and community members participate in the lighthearted event raising tens of thousands ...

FRANKFURT, March 9 (Reuters) - Roche's shares dropped more than 7% at one stage on Monday, their biggest decline in nearly a ...

FRANKFURT, March 9 (Reuters) - Roche's shares dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...